Sucampo shares slide after its lead experimental drug flunks a PhIIa test

Sucampo

Shares of Sucampo Pharmaceuticals ($SCMP) slumped Tuesday morning after the biotech reported that its lead experimental drug flubbed a Phase IIa trial, forcing investigators to shutter the program.

Sucampo’s stock was down about 20% in premarket trading as investors reacted to the news that cobiprostone failed to meaningfully improve heartburn symptoms for proton pump inhibitor-resistant non-erosive reflux disease (NERD) or symptomatic gastroesophageal reflux disease (sGERD).

But the drug--a chloride channel activator--isn’t dead.

Virtual Event

Virtual Clinical Trials Online

This virtual event will bring together industry experts to discuss the increasing pace of pharmaceutical innovation, the need to maintain data quality and integrity as new technologies are implemented and understand regulatory challenges to ensure compliance.

“While these data did not support the advancement of cobiprostone in this indication, the data did demonstrate that cobiprostone was well-tolerated, and this is consistent with our earlier Phase I studies,” said Rockville, MD-based Sucampo CSO Peter Kiener in a statement. “We plan to continue our development of cobiprostone in our ongoing Phase IIa study for the prevention of oral mucositis--a disorder with very different underlying pathophysiology and clinical endpoints. This development plan includes a futility analysis on the ongoing trial in the second half of this year.”

Sucampo has been developing a market for its constipation drug Amitiza. Jason Gerberry at Leerink recently estimated 2019 sales of that drug at $500 million, adding that the cobiprostone study was probably its most important pipeline catalyst this year.

Read more on

Suggested Articles

Millions of tests are urgently needed as the virus keeps communities across the country in lockdown and hospitals are overwhelmed with patients.

The FDA granted its first emergency authorization for a rapid antibody blood test for COVID-19 developed by Cellex.

Cancer biotech Zentalis Pharmaceuticals priced its IPO at $165 million, eclipsing the $100 million goal it laid out in early March.